Title:
FAM13A is a modifier gene of cystic fibrosis lung phenotype regulating rhoa activity, actin cytoskeleton dynamics and epithelial-mesenchymal transition

Authors:
Harriet Corvol¹, ², Nathalie Rousselet¹, Kristin E. Thompson¹, Laura Berdah¹, Guillaume Cottin¹, Tobias Foussigniere³, Elisabeth Longchampt³, Laurence Fiette⁴, Edouard Sage⁵, Céline Prunier¹, Mitchell Drumm⁶, Craig A. Hodges⁶, Pierre-Yves Boëlle⁷, Loic Guillot¹

Affiliations:
¹Sorbonne Universités, UPMC Univ Paris 06, INSERM, Centre de Recherche Saint-Antoine (CRSA), Paris 75012 France;
²Pneumologie pédiatrique, APHP, Hôpital Trousseau, Paris 75012, France;
³Service d'Anatomie Pathologique, Hôpital Foch, Suresnes 92150, France;
⁴Histopathologie humaine et modèles animaux, Institut Pasteur, Paris 75015, France;
⁵Département de chirurgie thoracique et transplantation pulmonaire, Hôpital Foch, Suresnes 92150, France;
⁶Department of Pediatrics and Department of Genetics and Genome Sciences, Case Western Reserve University, Cleveland, OH 44106, USA;
⁷INSERM, UMR_S 1136, Institut Pierre Louis d'Epidémiologie et de Santé Publique, Sorbonne Universités, UPMC Univ Paris 06, Paris 75012, France.

What was your research question?
Although cystic fibrosis (CF) is due to mutations in the CFTR gene, considerable disease variability among patients suggests the influence of other genes called “modifier genes”. In this study, we ask if the FAM13A gene influences lung disease severity of CF patients and what is its function in the lung.

Why is this important?
It is estimated that modifier genes could contribute up to 50% of the lung function variability. Previous genetic studies have already identified the location of several of these modifier genes, but few have evaluated their functions. The characterization of modifier genes, such as FAM13A, will offer not only a better understanding of their function in the lung but may also help to discover new therapeutics targets.
Cystic Fibrosis Research News

What did you do?
To determine if FAM13A influences the lung function of CF patients, we performed a genetic analysis in a large cohort of 1,222 French CF patients. Next, we performed in vitro studies in order to understand the presumptive biological role of FAM13A in the lung. These studies were done with epithelial cells isolated from the lung and inflammatory molecules known to be important in CF disease. To understand the function of FAM13A, we decreased its expression in lung cells and examined the consequences on the cell behaviour such as the epithelial cell morphology.

What did you find?
We found that FAM13A was indeed a modifier gene of CF lung function. We observed that the FAM13A protein was expressed in lung epithelial cells and that the inflammatory context of CF induced a decrease of its expression. Finally, we observed that lung epithelial cells exhibited a change in their morphology when the expression of FAM13A was reduced.

What does this mean and reasons for caution?
This work indicates that FAM13A plays a role in the lung function of CF patients. The contribution of this gene to lung function is however relatively small and more work is needed to explain how FAM13 may influence the lung function of CF patients. Our in vitro experiments suggest that FAM13A protein is important for the cell architecture and possibly to the lung tissue integrity. The limitations are the use of isolated cells from the lung, which may not reflect the role of FAM13A in the lung in vivo.

What’s next?
In order to have a better understanding of the role of FAM13A on the lung function of CF patients, further studies will decipher if FAM13A has an impact on CFTR function in vitro and in vivo.

Original manuscript citation in PubMed